Management of docetaxel failures in metastatic castrate-resistant prostate cancer.

Abstract

The treatment of metastatic castration-resistant prostate cancer has evolved since the approval of docetaxel-based therapy. Since docetaxel approval, three new agents have gained approval for this indication: sipuleucel-T, cabazitaxel, and abiraterone. Recent Phase III trials have also demonstrated survival benefits for MDV-3100 and radium-223 though regulatory approval ispending. Practicing physicians face the challenge of determining the optimal sequencing of these new agents. This dilemma is particularly relevant to the post-docetaxel setting, in which the indication for several of these agents overlaps. This article details the efficacy and safety of these agents to provide a framework for their clinical use.

• Authors: Sumanta K Pal, Brian Lewis, Oliver Sartor
• Journal: The Urologic clinics of North America (Urol Clin North Am) Vol. 39 Issue 4 Pg. 583-91 (Nov 2012) ISSN: 1558-318X [Electronic] United States
• PMID: 23084533 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
• Copyright: Copyright © 2012 Elsevier Inc. All rights reserved.

Chemical References

• Androstenes
• Androstenols
• Antineoplastic Agents
• Benzamides
• Nitriles
• Receptors, Androgen
• Taxoids
• Docetaxel
• Phenylthiohydantoin
• cabazitaxel
• enzalutamide
• Steroid 17-alpha-Hydroxylase
• abiraterone
• Radium

Topics

• Androstenes
• Androstenols (pharmacology, therapeutic use)
• Antineoplastic Agents (administration & dosage, chemistry, pharmacology, therapeutic use)
• Benzamides
• Docetaxel
• Humans
• Male
• Neoplasms, Hormone-Dependent
• Nitriles
• Phenylthiohydantoin (analogs & derivatives, pharmacology)
• Prostatic Neoplasms (drug therapy, secondary)
• Radium (therapeutic use)
• Receptors, Androgen (drug effects)
• Steroid 17-alpha-Hydroxylase (drug effects)
• Taxoids (administration & dosage, chemistry, therapeutic use)
• Treatment Failure